Estrogeny i kostnaya tkan'


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

In physiology and pathophysiology of bone tissue, systemic and local factors play an important role. The article presents information on the role of estrogen in the function of bone tissue. Some issues of the etiology, pathogenesis, and diagnostic principles of postmenopausal osteoporosis are discussed. With regard to current views on the impact of the combined treatment and monotherapy with estrogen on bone mineral density and fracture risk, problems of prevention and treatment of osteoporosis are considered.

全文:

受限制的访问

参考

  1. Manogalas SC, Drezner MK, Mulder JE. Normal skeletal development and regulation of bone formation and resorption. Up to Date 2012.
  2. Primer on the Metabolic Bone Disease of Mineral Metabolism (7th Edition). Ed. Rosen CJ, Compston JE, Lian BL. The USA, 2008:537.
  3. Di Vasta AD, Gordon CM. Bone health in adolescents. Adolesc Med Clin 2006;17: 639-52.
  4. Eriksen EF, Colvard DS, Berg NJ, et al. Evidence of estrogen receptors in normal human osteoblastlike cells. Science 1988;341:84-6.
  5. Bland R. Steroid hormone receptor expression and action on bone. Clin Sci 2000;57:635-42.
  6. Lories RJU, Lyuten FP. Osteoprotegerin and osteoprotegerin-ligand balance: a new paradigm in bone metabolism providing new therapeutic targets. Clin Rheum 2001;(20):3-9.
  7. Tolar J, Teitelbaum SL, Orchard PJ. Mechanisms of disease: Osteopetrosis. N Engl J Med 2004;351:2839-49.
  8. Taes Y, Lapauw B, Vandewalle S, et al. Estrogenspecific action on bone geometry and volumetric bone density: longitudinal observations in an adult with complete androgen insensitivity. Bone 2009;45:392-97.
  9. Giner M, Rios MA, Montoya MA, et al. RANKL/ OPG in primary cultures of osteoblasts from postmenopausal women. Differences between osteoporotic hip fractures and osteoathritis. J Steroid Biochem Mol Biol 2009; 113:46-51.
  10. Meczekalski B, Podfigurna-Stopa A, Genazzani AR. Hypoestrogenism in young women and its influence on bone mass density. Gynecol Endocr 2010;26(9):652-57.
  11. Piscitelli P, Rigliano V, Neglia C, et al. Early menopause influences osteopenic or osteoporotic status in postmenopausal women: preliminary results from PROF project. Osteoporosis International 2010;21(1):S53.
  12. Manogalas SC, Rosen CJ, Mulder JE. Pathogenesis of osteoporosis. Up to Date 2012.
  13. Глава Постменопаузальный остеопороз в кн. Медицина климактерия / Под ред. В.П. Сметник. Ярославль, 2006. С. 656-727.
  14. Greenspan SL, Emkey RD, Bone HG, et al. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double blind, placebo-controlled trial. Ann Int Med 2002;137:875-83.
  15. Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008;19:399-428.
  16. Mosekilde L, Vestergaard P, Langdahl B. Fracture prevention in postmenopausal women. BMJ Clin Evid 2008;1:1109-34.
  17. Pinkerton JV, Pickar JH, Racketa J, et al. Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention. Climacteric 2012;15(5):411-18.
  18. Дьяконова А.А. Заместительная гормональная терапия некоторых поздних обменно-трофических нарушений у женщин в постменопаузе: Дисс. канд. мед. наук. М., 2001. 153 с.
  19. Rossow JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321-33.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2013
##common.cookie##